ImmunityBio, Inc. is a commercial-stage biotechnology company headquartered in San Diego, California, developing immunotherapies designed to harness natural immune system function against cancers and infectious diseases. The company operates multiple therapeutic platforms centered on cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. These platforms have generated first-in-human therapeutic candidates under evaluation in clinical trials targeting both liquid and solid tumors.
The company's primary marketed product is Anktiva, an FDA-approved immunotherapy for treating adult patients with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ. Anktiva is administered in combination with bacillus calmette-guérin (BCG) and represents the company's lead biologic product generating commercial revenue.
ImmunityBio operates at a scale of 673 full-time employees and maintains strategic partnerships with the National Cancer Institute, Serum Institute of India Private Limited, and BeiGene, Ltd. The company is incorporated in Delaware and listed on Nasdaq.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2025 | $-0.38 | $-0.38 | +38.7% | |
| 2024 | $-0.62 | $-0.59 | +46.1% | |
| 2023 | $-1.15 | $-1.15 | -10.6% | |
| 2022 | $-1.04 | $-1.04 | -16.9% | |
| 2021 | $-0.89 | $-0.89 | — | |
| 2020 | — | — | — | |
| 2019 | — | — | — | |
| 2018 | — | — | — | |
| 2017 | — | — | — | |
| 2016 | — | — | — | |
| 2015 | — | — | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2025-12-31 | 2026-02-23 | 0001326110-26-000030 | SEC ↗ |
| 2024-12-31 | 2025-03-03 | 0001326110-25-000033 | SEC ↗ |
| 2023-12-31 | 2024-03-19 | 0001326110-24-000037 | SEC ↗ |
| 2022-12-31 | 2023-03-01 | 0001326110-23-000018 | SEC ↗ |
| 2021-12-31 | 2022-03-01 | 0001326110-22-000011 | SEC ↗ |
| 2020-12-31 | 2021-03-04 | 0001564590-21-010945 | SEC ↗ |
| 2019-12-31 | 2020-03-25 | 0001564590-20-012816 | SEC ↗ |
| 2018-12-31 | 2019-03-13 | 0001564590-19-007562 | SEC ↗ |
| 2017-12-31 | 2018-03-12 | 0001564590-18-005290 | SEC ↗ |
| 2016-12-31 | 2017-03-15 | 0001564590-17-004430 | SEC ↗ |
| 2015-12-31 | 2016-03-30 | 0001564590-16-015596 | SEC ↗ |